Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Average Rating of “Buy” from Brokerages

Avalyn Pharma Inc. (NASDAQ:AVLN) has received a consensus rating of “Buy” from the five analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $59.00.

A number of research firms have issued reports on AVLN. Wall Street Zen raised Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Morgan Stanley began coverage on Avalyn Pharma in a report on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 price target for the company. Zacks Research raised Avalyn Pharma to a “hold” rating in a report on Wednesday, May 27th. Guggenheim began coverage on Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $80.00 price target for the company. Finally, Jefferies Financial Group began coverage on Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $52.00 price target for the company.

Insider Activity at Avalyn Pharma

In other news, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the business’s stock in a transaction on Friday, May 1st. The stock was purchased at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the acquisition, the insider directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. The trade was a 34.06% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jill Carroll purchased 277,778 shares of the business’s stock in a transaction on Friday, May 1st. The stock was purchased at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the acquisition, the director owned 2,186,562 shares in the company, valued at approximately $39,358,116. This represents a 14.55% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Avalyn Pharma Stock Up 2.6%

AVLN opened at $27.09 on Friday. Avalyn Pharma has a 12-month low of $24.15 and a 12-month high of $32.22.

Avalyn Pharma (NASDAQ:AVLN) last released its earnings results on Wednesday, June 3rd. The company reported ($21.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45).

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.